Please login to the form below

Not currently logged in
Email:
Password:

Genzyme wins Scottish approval for Renvela

Genzyme UK can supply Renvela within NHS Scotland after securing Scottish Medicine Consortium approval

Genzyme UK, a subsidiary of sanofi-aventis group, has received approval from the Scottish Medicine Consortium (SMC) to use Renvela within NHS Scotland as a treatment for hyperphosphataemia in adult patients with chronic kidney disease (CKD).

Renvela is a medication for the control of serum phosphorous in patients with CKD. Kidney failure causes levels of phosphate to rise in the blood, as the patient's kidneys are not able to excrete excess phosphate into the urine. Phosphorous build up is also associated with calcification of certain vessels.

Dr Alan Jardine, professor of renal medicine and head of the undergraduate medical school at University of Glasgow, said: "The availability of Renvela offers an efficacious addition to this class of agent, where existing therapies may have limited efficacy and poor patient compliance."

13th April 2011

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics